Cargando…

Diffuse Lung Metastases in EGFR-Mutant Non-Small Cell Lung Cancer

Diffuse lung metastases have been reported in non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations. The purpose of our study was to compare the incidence of diffuse lung metastases in EGFR-mutant NSCLC and EGFR-wild type NSCLC and to assess other imaging fea...

Descripción completa

Detalles Bibliográficos
Autores principales:	Digumarthy, Subba R., Mendoza, Dexter P., Padole, Atul, Chen, Tianqi, Peterson, P. Gabriel, Piotrowska, Zofia, Sequist, Lecia V.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6769768/ https://www.ncbi.nlm.nih.gov/pubmed/31540242 http://dx.doi.org/10.3390/cancers11091360

Ejemplares similares

Can CT radiomic analysis in NSCLC predict histology and EGFR mutation status?
por: Digumarthy, Subba R., et al.
Publicado: (2019)

Role of imaging biomarkers in mutation-driven non-small cell lung cancer
por: Mendoza, Dexter P, et al.
Publicado: (2020)

Radiomic features of primary tumor by lung cancer stage: analysis in BRAF mutated non-small cell lung cancer
por: Padole, Atul, et al.
Publicado: (2020)

Predicting malignant potential of subsolid nodules: can radiomics preempt longitudinal follow up CT?
por: Digumarthy, Subba R., et al.
Publicado: (2019)

Cardiac Risk-Informed Treatment of EGFR-Mutant Lung Cancer With Osimertinib
por: Piper-Vallillo, Andrew J., et al.
Publicado: (2019)

Safety and Success of Repeat Lung Needle Biopsies in Patients with Epidermal Growth Factor Receptor‐Mutant Lung Cancer
por: Fintelmann, Florian J., et al.
Publicado: (2019)

CT texture analysis of histologically proven benign and malignant lung lesions
por: Digumarthy, Subba R., et al.
Publicado: (2018)

Clinical Utility of Rapid EGFR Genotyping in Advanced Lung Cancer
por: Dagogo-Jack, Ibiayi, et al.
Publicado: (2018)

Targeting FGFR overcomes EMT-mediated resistance in EGFR mutant non-small cell lung cancer
por: Raoof, Sana, et al.
Publicado: (2019)

Clinicopathologic and Imaging Features of Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations
por: Digumarthy, Subba R., et al.
Publicado: (2019)

Combatting acquired resistance to osimertinib in EGFR-mutant lung cancer
por: Lee, Jiyun, et al.
Publicado: (2022)

Acquired Resistance of EGFR-Mutated Lung Cancer to Tyrosine Kinase Inhibitor Treatment Promotes PARP Inhibitor Sensitivity
por: Marcar, Lynnette, et al.
Publicado: (2019)

RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer
por: Niederst, Matthew J., et al.
Publicado: (2015)

Germline mutations and developmental mosaicism underlying EGFR-mutant lung cancer
por: Burr, Risa, et al.
Publicado: (2023)

Efficacy and Tolerability of ALK/MET Combinations in Patients With ALK-Rearranged Lung Cancer With Acquired MET Amplification: A Retrospective Analysis
por: Dagogo-Jack, Ibiayi, et al.
Publicado: (2023)

Revolving Door of Histologic Transformation—Tumor Heterogeneity Complicating the Management of EGFR-Mutated Lung Adenocarcinoma: A Case of Jekyll and Hyde
por: Wysota, Michael, et al.
Publicado: (2020)

Imaging Features and Patterns of Metastasis in Non-Small Cell Lung Cancer with RET Rearrangements
por: Digumarthy, Subba R., et al.
Publicado: (2020)

Detection of EGFR Mutations in Cerebrospinal Fluid of EGFR-Mutant Lung Adenocarcinoma With Brain Metastases
por: Shi, Liang, et al.
Publicado: (2021)

Clinical and Imaging Features of Non-Small Cell Lung Cancer with G12C KRAS Mutation
por: Wu, Markus Y., et al.
Publicado: (2021)

Coronavirus Disease 2019 Infection in a Patient Population with Lung Cancer: Incidence, Presentation, and Alternative Diagnostic Considerations
por: Piper-Vallillo, Andrew J., et al.
Publicado: (2020)

Clinicopathologic Characteristics and Outcomes for Patients With KRAS G12D-Mutant NSCLC
por: Cooper, Alissa J., et al.
Publicado: (2022)

Neurological Death is Common in Patients With EGFR Mutant Non-Small Cell Lung Cancer Diagnosed With Brain Metastases
por: Ramotar, Matthew, et al.
Publicado: (2019)

Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients
por: Chabon, Jacob J., et al.
Publicado: (2016)

Expression of EGFR-mutant proteins and genomic evolution in EGFR-mutant transformed small cell lung cancer
por: Zhang, Shi-Ling, et al.
Publicado: (2023)

Upfront whole brain radiotherapy for multiple brain metastases in patients with EGFR-mutant lung adenocarcinoma
por: Li, Changhui, et al.
Publicado: (2019)

Does EGFR Mutation Type Influence Patient-Reported Outcomes in Patients with Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer? Analysis of Two Large, Phase III Studies Comparing Afatinib with Chemotherapy (LUX-Lung 3 and LUX-Lung 6)
por: Wu, Yi-Long, et al.
Publicado: (2017)

Corrigendum: Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients
por: Chabon, Jacob J., et al.
Publicado: (2016)

EGFR mutation detection in circulating cell-free DNA of lung adenocarcinoma patients: analysis of LUX-Lung 3 and 6
por: Wu, Yi-Long, et al.
Publicado: (2017)

Effects of icotinib with and without radiation therapy on patients with EGFR mutant non-small cell lung cancer and brain metastases
por: Fan, Yun, et al.
Publicado: (2017)

A Neuro-oncologist’s Perspective on Management of Brain Metastases in Patients with EGFR Mutant Non-small Cell Lung Cancer
por: McGranahan, Tresa, et al.
Publicado: (2017)

Extrathoracic Metastases in Pleural Mesothelioma
por: Dagogo-Jack, Ibiayi, et al.
Publicado: (2023)

Treatment outcomes of EGFR-TKI with or without locoregional brain therapy in advanced EGFR-mutant non-small cell lung cancer patients with brain metastases
por: Linh, Do Mai, et al.
Publicado: (2023)

Efficacy of nano‐particulated, water‐soluble erlotinib against intracranial metastases of EGFR‐mutant lung cancer
por: Kim, Dong Ha, et al.
Publicado: (2018)

71. MGMT PROMOTER METHYLATION IS A PROGNOSTIC BIOMARKER IN EGFR MUTANT LUNG ADENOCARCINOMA WITH BRAIN METASTASES
por: Mamatjan, Yasin, et al.
Publicado: (2020)

Outcomes of salvage lung resections in advanced EGFR ‐mutant lung adenocarcinomas under EGFR TKIs
por: Chen, Ying‐Yuan, et al.
Publicado: (2021)

Clonal Evolution and Heterogeneity of Osimertinib Acquired Resistance Mechanisms in EGFR Mutant Lung Cancer
por: Roper, Nitin, et al.
Publicado: (2020)

Activity of Adagrasib (MRTX849) in Brain Metastases: Preclinical Models and Clinical Data from Patients with KRAS(G12C)-Mutant Non–Small Cell Lung Cancer
por: Sabari, Joshua K., et al.
Publicado: (2022)

Standard-dose osimertinib for refractory leptomeningeal metastases in T790M-positive EGFR-mutant non-small cell lung cancer
por: Nanjo, Shigeki, et al.
Publicado: (2018)

Efficacy and safety of osimertinib for leptomeningeal metastases from EGFR-mutant non-small cell lung cancer: a pooled analysis
por: Wen, Lei, et al.
Publicado: (2023)

Deep learning in chest radiography: Detection of findings and presence of change
por: Singh, Ramandeep, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_f1mruihhetknge2eptptamf676